文献速递肿瘤 PET/CT放射性药物与辐射防护

FDG PET/CT在侵袭性真菌感染治疗反应监测中的作用

Role of FDG PET/CT in monitoring treatment response in patients with invasive fungal infections.
PubMed 文献 · Eur J Nucl Med Mol Imaging · 2018-10-21

该回顾性研究纳入2009年10月至2018年3月间诊断为侵袭性真菌感染并接受抗真菌药物治疗、且在基线和治疗期间一个或多个时间点行FDG-PET/CT的患者,评估FDG-PET/CT在监测IFI和治疗决策中的作用及基线代谢参数预测代谢反应的价值。结果显示FDG-PET/CT改变了50%(14/28)患者的管理,最终扫描时68%(19/28)达完全代谢反应;基线TLG和MV可预测完全代谢反应。

要点

  • FDG-PET/CT改变了50%(14/28)侵袭性真菌感染患者的管理。
  • 最终FDG-PET/CT扫描时68%(19/28)患者达完全代谢反应。
  • 基线TLG截断值160预测完全代谢反应的灵敏度94%、特异度100%(p<0.001)。

核心结论

  • FDG-PET/CT有助于监测侵袭性真菌感染,使半数患者的管理治疗发生改变。
  • 基线TLG和MV能够预测抗真菌治疗的代谢反应。

研究设计与样本

  • 回顾性纳入2009年10月至2018年3月诊断为侵袭性真菌感染、接受抗真菌药物治疗并在基线和治疗期间一个或多个时间点行FDG-PET/CT的患者。
  • 共纳入28例患者,总计98次FDG-PET/CT扫描,平均年龄43±22岁。
  • 所有FDG-PET/CT扫描按EANM/EARL标准化方案进行。
  • 通过扫描后的临床决策评估FDG-PET/CT监测抗真菌治疗的作用,并评估基线代谢参数预测代谢反应的附加价值。

主要发现

  • FDG-PET/CT改变了14/28例(50%)患者的管理。
  • 最终FDG-PET/CT扫描时19例(68%)达完全代谢反应,7例部分反应,2例定义为进展性疾病。
  • 基线TLG预测完全代谢反应的截断值160,灵敏度94%,特异度100%,p<0.001。
  • 基线MV预测完全代谢反应的截断值60,灵敏度84%,特异度75%,p=0.001。

关键数值与推荐

  • 基线TLG截断值160,灵敏度94%,特异度100%,p<0.001,用于区分达完全代谢反应的患者。
  • 基线MV截断值60,灵敏度84%,特异度75%,p=0.001,用于区分达完全代谢反应的患者。

临床怎么用

  • FDG-PET/CT可用于监测侵袭性真菌感染并辅助治疗决策,研究中使半数患者的管理治疗发生改变。
  • 基线TLG和MV可能有助于预测抗真菌治疗的代谢反应。

局限性

  • 原文未述局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: Invasive fungal infections (IFIs) occur mostly in immunosuppressed patients and can be life-threatening. Inadequate treatment is associated with high morbidity and mortality. We examined the role of 2-fluorodeoxyglucose positron emission tomography integrated with CT (FDG-PET/CT) in monitoring IFIs and therapy decision-making, and evaluated the role of baseline metabolic parameters in predicting the metabolic response. METHODS: All patients between October 2009 and March 2018, diagnosed with IFIs, treated with antifungal drugs, and who underwent FDG-PET/CT at baseline and at one or more timepoints during treatment were retrospectively included. The electronic patient files were reviewed for pathology, microbiology, and laboratory findings. All FDG-PET/CT scans were performed according to standardized European Association of Nuclear Medicine/EANM Research Limited (EANM/EARL) protocols. For each scan, the global total lesion glycolysis (TLG) and metabolic volume (MV), highest maximum standardized uptake value (SUVmax), and peak standardized uptake value (SUVpeak) were determined. The role of FDG-PET/CT on monitoring antifungal therapy was assessed by looking at the clinical decision made as result of the scan. Furthermore, the added value of the baseline metabolic parameters in predicting metabolic response to the antifungal treatment was evaluated. RESULTS: Twenty-eight patients with in total 98 FDG-PET/CT scans were included with a mean age of 43 ± 22 years. FDG-PET/CT altered management in 14 out of the 28 patients (50%). At the final FDG-PET/CT scan, 19 (68%) had a complete metabolic response (CMR), seven a partial response and two patients were defined as having progressive disease. Using receiver operative analysis, the cut-off value, sensitivity, specificity, and significance for the baseline TLG and MV to discriminate patients with CMR were 160, 94%, 100%, p < 0.001 and 60, 84%, 75%, p = 0.001 respectively. CONCLUSION: FDG-PET/CT is useful in the monitoring of IFIs resulting in management therapy change in half of the patients. Baseline TLG and MV were found to be able to predict the metabolic response to antifungal treatment.

来源:Eur J Nucl Med Mol Imaging,查看原文。版权归原作者所有。

引用

  1. Ankrah AO, Span LFR, Klein HC, et al. Role of FDG PET/CT in monitoring treatment response in patients with invasive fungal infections. Eur J Nucl Med Mol Imaging. 2018. PMID: 30343434. doi:10.1007/s00259-018-4192-z

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。